CMV Product overview

Cyto-Barr has developed innovative synthetic peptide-based tools with proven value for HCMV serodiagnosis in various clinical settings, including congenital infections, the organ-transplant setting and HIV-AIDS patients.
In addition we have developed RNA-based markers for a "traffic-light approach" in monitoring the potential life-threatening HCMV activity in high risk groups.

Cyto-Barr developed and owns the original hybridomas used for pp65-antigenaemia testing and detection of cytomegalic cells is tissues by immunohistochemistry.